Serum Pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

Journal of Urology

Volumn 170, Issue 6 I, 2003, Pages 2181-2185

  Catalona, William J ^a,d   Bartsch, Georg ^b   Rittenhouse, Harry G ^c   Evans, Cindy L ^c   Linton, Harry J ^c   Amirkhan, Anna ^c   Horninger, Wolfgang ^b   Klocker, Helmut ^b   Mikolajczyk, Stephen D ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c BECKMAN COULTER INC   (United States)

^d Department of Urology ^*  (United States)

Author keywords

Antibodies; Immunoassay; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PRO PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

EID: 0242692670     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000095460.12999.43     Document Type: Article

References (20)

1. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 324: 1156, 1991
2. Tchetgen, M. B. and Oesterling, J. E.: The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am, 24: 283, 1997
3. Emiliozzi, P., Longhi, S., Scarpone, P., Pansadoro, A., DePaula, F. and Pansadoro, V.: The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol, 166: 845, 2001
4. Roehl, K. A., Antenor, J. A. V. and Catalona, W. J.: Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2. 6 to 4.0 ng./ml. range. J Urol, 168: 922, 2002
5. Okihara, K., Fritsche, H. A., Ayala, A., Johnston, D. A., Allard, W. J. and Babaian, R. J.: Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol, 165: 1930, 2001
6. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res, 51: 222, 1991
7. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A. et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multi-center clinical trial. JAMA, 279: 1542, 1998
8. Catalona, W. J., Partin, A. W., Finlay, J. A., Chan, D. W., Rittenhouse, H. G., Wolfert, R. L. et al: Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2. 51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology, 54: 220, 1999
9. Mikolajczyk, S. D., Marks, L. S., Partin, A. W. and Rittenhouse, H. G.: Free prostate-specific antigen in serum is becoming more complex. Urology, 59: 797, 2002
10. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Rittenhouse, H. G., Marks, L. S., Song, W. et al: A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res, 60: 756, 2000
11. Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., Hill, T. M., Kumar, A., Rittenhouse, H. G. et al: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology, 50: 710, 1997
12. Mikolajczyk, S. D., Marker, K. M., Millar, L. S., Kumar, A., Saedi, M. S., Payne, J. K. et al: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res, 61: 6958, 2001
13. Peter, J., Unverzagt, C., Krogh, T. N., Vorm, O. and Hoesel, W.: Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res, 61: 957, 2001
14. Khan, M., Partin, A., Rittenhouse, H., Mikolajczyk, S., Sokoll, L., Chan, D. et al: Evaluation of pro-PSA for early detection of prostate cancer in men with a total PSA range of 4.0-10.0 ng/ml. Unpublished data
15. Sokoll, L. J., Chan, D. W., Mikolajczyk, S. D., Rittenhouse, H. G., Evans, C. L., Linton, H. J. et al: Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology, 61: 274, 2003
16. Tanguay, S., Begin, L. R., Elhilali, M. M., Behlouli, H., Karakiewicz, P. I. and Aprikian, A. G.: Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology, 59: 261, 2002
17. Okihara, K., Cheli, C. D., Partin, A. W., Fritche, H. A., Chan, D. W., Sokoll, L. J. et al: Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol, 167: 2017, 2002
18. Miller, M. C., O'Dowd, G. J., Partin, A. W. and Veltri, R. W.: Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology, 57: 1105, 2001
19. Bunting, P. S., DeBoer, G., Choo, R., Danjoux, C., Klotz, L. and Fleshner, N.: Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem, 35: 471, 2002
20. Espana, F., Martinez, M., Royo, M., Estelles, A., Alapont, J. M., Navarro, S. et al: Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int, 90: 672, 2002